In its fiscal third quarter, Agilent delivered 7% core revenue growth, above its prior 4% to 6% outlook, and adjusted EPS growth of 18% to $1.62, including $0.06 in tariff refunds, but still above its prior guidance of $1.48-$1.50. Management also raised its full-year 2026 guidance.
Agilent's innovation engine and cost control efforts have been on display through strong growth and margin expansion since spinning out its electronic measurement business Keysight in November 2014.
Due to its dependence on one-time sales and its exposure to some cyclical end markets, Agilent's financial results may weaken during uncertain times.
|
Metric
|
A
|
WAT
|
DHR
|
|---|---|---|---|
Price/Earnings (Normalized) | 27.50 | 31.11 | 26.08 |
Price/Book Value | 6.38 | 2.75 | 2.83 |
Price/Sales | 6.41 | 6.86 | 6.00 |
Price/Cash Flow | 24.91 | 26.54 | 21.01 |
|
Metric
|
A
|
WAT
|
DHR
|
|---|---|---|---|
Quick Ratio | 1.41 | 1.05 | 1.03 |
Current Ratio | 2.05 | 1.86 | 1.65 |
Interest Coverage | 16.08 | 2.23 | 16.95 |
|
Metric
|
A
|
WAT
|
DHR
|
|---|---|---|---|
Return on Assets (Normalized) | 13.27% | 7.79% | 5.34% |
Return on Equity (Normalized) | 24.92% | 13.28% | 8.59% |
Return on Invested Capital (Normalized) | 16.95% | 10.35% | 6.45% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|h?dx>M>r | LOCK|V! | $241B | |||
| Danaher Corp
DHR
| LOCK|n&wJ^@m$ | LOCK|p! | $149B | |||
| IQVIA Holdings Inc
IQV
| LOCK|wB<Y@k% | LOCK|?BR?L | $43B | |||
| Waters Corp
WAT
| LOCK|?#phNg | LOCK|pZ^ | $42B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|NC@>?#tR | LOCK|tN? | $41B | |||
| Illumina Inc
ILMN
| LOCK|x%d$LP | LOCK|>S#$ | $40B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|?Z@<tT$% | LOCK|@g#Y | $30B | |||
| Quest Diagnostics Inc
DGX
| LOCK|gz?hq> | LOCK|@%W% | $26B | |||
| Labcorp Holdings Inc
LH
| LOCK|!?gNTs<# | LOCK|Z@QZ | $25B |
United States